Exelixis Inc. (NasdaqGS: EXEL) improved in price by 29.66 percent in Thursday afternoon trade to $6.12 Volume of 11,806,150 shares proved about 12 times the stock’s three-month daily average. The drug maker Thursday reported interim data from the cohort of patients with advanced epithelial ovarian cancer, primary peritoneal, or fallopian tube carcinoma treated with XL184 in an ongoing phase 2 adaptive randomized discontinuation trial (RDT).

Sirius XM Radio Inc. (NasdaqGS: SIRI) was a volume leader Thursday afternoon, with 47,602,492 shares changing hands, against its usual daily volume of 75,126,200 shares. SIRI shares added 3.70 percent Thursday in price to $1.40.

Aastrom Biosciences Inc. (NasdaqCM: ASTM) fell in price Thursday by 22.14 percent to $3.27. Volume of 4,182,850 shares trampled over usual daily volume of 1,068,090 shares. The Michigan-based developer of expanded autologous cellular therapies today announced that an interim analysis of all 86 patients enrolled in the company’s Phase 2b RESTORE-CLI clinical trial shows that the study achieved both its primary safety endpoint and primary efficacy endpoint of time to first occurrence of treatment failure.